Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
View Scopus Profile
Wei Tan
Research Scientist
Lymphoma-Myeloma
https://orcid.org/0000-0002-5308-6085
h-index
229
Citations
6
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
2019
2024
Research activity per year
Overview
Fingerprint
Network
Research output
(6)
Fingerprint
Dive into the research topics where Wei Tan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Genome Instability
98%
AMP-activated Protein Kinase
61%
Serine
53%
Cell Metabolism
51%
Homologous Recombination
46%
Geminin
46%
Nucleotide Metabolism
46%
DNA Synthesis
46%
Tumor Suppressor Gene
46%
Recombination Repair
46%
USP15
46%
Deubiquitylating Enzyme
46%
Poly ADP Ribose Polymerase
46%
DNA Damage
46%
Arginine
46%
Posttranscriptional Regulation
46%
Ribose-Phosphate Diphosphokinase
46%
Cell Cycle Regulation
46%
Physiological Process
46%
Lipogenesis
46%
Protein Kinase
36%
S Phase
30%
Karyopherin
27%
Importin
27%
BARD1
23%
Transferase
19%
Nuclear Localization Sequence
18%
Posttranslational Modification
18%
Promoter Region
15%
Oncogene C Myc
15%
Cell Cycle
15%
Glucosamine
14%
BRCA1
11%
MDC1
11%
Transgenic Mouse
10%
Nuclear Import
9%
RNA Splicing
9%
Precursor mRNA
9%
Cell Fate
9%
Helicase
7%
Anaphase
7%
Cell Cycle M Phase
7%
Mitosis
7%
Anaphase-Promoting Complex
7%
MicroRNA
7%
Cell Cycle Progression
7%
G1 Phase
7%
Knockout Mouse
5%
BRCT Domain
5%
Keyphrases
Breast Cancer
57%
Cancer Cells
55%
Genome Stability
55%
Molecular Mechanism
46%
O-GlcNAcylation
46%
DNA Replication
46%
Post-transcriptional Regulation
46%
Geminin
46%
Deubiquitinating Enzyme
46%
Repair Cell
46%
Homologous Recombination Repair
46%
Breast Cancer Susceptibility Gene 1 (BRCA1)
46%
Cell Response
46%
USP15
46%
Molecular Therapeutics
46%
De-novo Lipogenesis
46%
PARP Inhibitor (PARPi)
46%
Arginine-rich
46%
Therapeutic Strategies
46%
Sigma Phase
36%
Protein Kinase 2
36%
Importin
27%
O-linked N-acetylglucosamine (O-GlcNAc)
27%
BARD1
23%
In Cancer
20%
Post-translational Modification
18%
MicroRNA
18%
Nuclear Localization Signal
18%
C-Myc
18%
DNA Re-replication
18%
Homologous Recombination
17%
Genomic Instability
14%
MDC1
11%
Ovarian Cancer
11%
Arts Syndrome
10%
Pre-mRNA
9%
Cyclin-dependent Kinase 2 (CDK2)
9%
G1 Phase
9%
Cycle Stability
9%
Human Cancer
9%
Lipogenic
9%
DNA Damage
9%
RNA Splicing
9%
M Phase
9%
Replication Complex
9%
Tumor Suppressor Gene
9%
Anaphase
9%
O-GlcNAc Transferase
9%
Molecular Regulation
9%
Cell Fate
9%
